Kymera Therapeutics (NASDAQ:KYMR) Stock Analysis: Deutsche Bank Sets $120 Price Target Amid Clinical Progress
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameKymera Therapeutics Inc
-
Registration countryUSA
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









